Close Menu
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

D.C.’s Most Expensive Home Sales of 2025 So Far

July 31, 2025

Blockchain Could Boost Covered Bonds, but Adoption Faces Major Hurdles: Moody’s

July 31, 2025

Pi Network price prediction for August 2025 – Can it reverse 75% losses? 

July 31, 2025
Facebook X (Twitter) Instagram
  • Contact Us
  • Privacy Policy
  • Terms Of Service
Thursday, July 31
Doorpickers
Facebook X (Twitter) Instagram
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking
Doorpickers
Home»Economic News»Novo Shares Ignite After Next-Gen Shot Shows 22% Weight Loss
Economic News

Novo Shares Ignite After Next-Gen Shot Shows 22% Weight Loss

January 24, 2025No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Novo Nordisk A/S experienced a significant surge in European trading following the announcement of positive early-stage trial results for its new obesity treatment, amycretin. The drug showed a remarkable 22% weight loss in patients over 36 weeks, boosting investor confidence and reversing negative sentiment. The once-weekly injection of amycretin outperformed a placebo, which resulted in a 2% weight gain in the same timeframe.

Martin Lange, Novo’s executive vice president for Development, expressed optimism about the trial results, highlighting the potential of amycretin as a novel treatment for obesity. The company’s shares saw a substantial increase of up to 14% in Copenhagen, marking the largest intra-day gain since August 8, 2023. Despite a recent decline in stock value, Novo’s super bull, Goldman’s James Quigley, remains bullish on the company, maintaining a “Buy” rating with a 875 Danish krone price target over the next 12 months.

Quigley emphasized the promising results of amycretin and its competitive edge in the obesity treatment market. He believes that further weight loss potential can be demonstrated over a longer period, potentially exceeding the initial 22% weight loss. The positive outlook on Novo’s future is a welcome change after the disappointment surrounding the company’s previous weight loss drug, CagriSema.

Barclays analyst Emily Field echoed Quigley’s sentiments, stating that Novo’s latest trial results have shifted the negative sentiment surrounding the company. The data indicates that amycretin could be a game-changer in the weight loss drug market, combining two effective mechanisms in a single molecule. This development comes at a crucial time as the industry navigates through changing dynamics, including the potential impact of new regulatory changes.

Overall, Novo Nordisk’s innovative approach to obesity treatment with amycretin has the potential to reinvigorate investor interest and position the company as a key player in the pharmaceutical market. As the company continues to advance its research and development efforts, the future looks promising for Novo and its groundbreaking obesity treatment.

Ignite Loss NextGen Novo Shares Shot shows weight
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Iran Plans To Abandon GPS & Replace With China’s BeiDou System

July 30, 2025

US GDP Jumps To 3.0% In Second Quarter, Trouncing Estimates And Reversing Q1 Contraction

July 30, 2025

Delusional Seattle Democrats Blame Trump While Ignoring Their Role In Homelessness Crisis

July 29, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Single-stock ETFs: How to earn even bigger profits on Magnificent 7 stocks

July 31, 20240 Views

“The American System” Made America Great

November 1, 20240 Views

When is Cyber Monday? Here’s What You Need To Know

November 18, 20240 Views
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest
Real Estate

D.C.’s Most Expensive Home Sales of 2025 So Far

July 31, 20250
Crypto

Blockchain Could Boost Covered Bonds, but Adoption Faces Major Hurdles: Moody’s

July 31, 20250
Crypto

Pi Network price prediction for August 2025 – Can it reverse 75% losses? 

July 31, 20250
Facebook X (Twitter) Instagram Pinterest
  • Contact Us
  • Privacy Policy
  • Terms Of Service
© 2025 doorpickers.com - All rights reserved

Type above and press Enter to search. Press Esc to cancel.